HGF and COVID-19: Consistent with this view, more than 90% of non-ICU patients with moderate respiratory syndrome have low HGF levels, thus identifying HGF as one of the critical pathogenic biomarkers for disease severity and the best predictor of the risk of ICU admission and death in COVID-19 sufferers.